Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
AANA Journal|September 8, 2009
Peer assistance reaches its 25th yearDiana Quinlan
Journal of Addictions Nursing|September 1, 2016
The Evolution of a Peer Assistance Network for Nurse Anesthetists' Substance Use DisorderLinda Stone, Diana Quinlan, Julie A Rice, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysisJames A Russell, A Robert Turner, Loree Larratt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2010
Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipientsAlejandra Ugarte-Torres, Mette Hoegh-Petersen, Yiping Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2008
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimenMichelle Geddes, S Bill Kangarloo, Farrukh Naveed, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulinJames A Russell, Mary Lynn Savoie, Alexander Balogh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2008
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk diseaseJames A Russell, Qiuli Duan, M Ahsan Chaudhry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2009
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemiaJames A Russell, William Irish, Alexander Balogh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2008
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamideChristopher N Bredeson, Mei-Jie Zhang, Manza-A Agovi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 2, 2011
Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosingS Bill Kangarloo, Farrukh Naveed, Ella S M Ng, et al.
Pageof 1